Please login to the form below

Not currently logged in
Email:
Password:

Inovio appoints Adel Mahmoud to board of directors

Former president of Merck Vaccines will advise on development of synthetic vaccines at US company

Adel Mahmoud - InovioInovio Pharmaceuticals has appointed former president of Merck Vaccines Dr Adel Mahmoud to its board of directors.

Dr Mahmoud spent six years in his vaccines position at Merck from 1999 to 2005, overseeing the development of human papillomavirus (HPV) vaccine Gardasil, one of the first vaccines developed to protect against cervical cancer.

Other vaccines developed during Mahmoud's time at Merck include Zostavax for shingles, Proquad for measles, mumps, rubella and chicken pox, and Rotateq, which protects against the rotavirus.

Dr J Joseph Kim, president and CEO of US-based Inovio, said: "Dr Mahmoud is known throughout the industry for his success in gaining approval for several blockbuster vaccines.  His insights will be advantageous to Inovio as we move our synthetic vaccine portfolio toward late-stage clinical trials."

This includes vaccines currently in development for cervical dysplasia, leukaemia, hepatitis C virus, influenza and HIV.

Dr Mahmoud is currently professor of the department of molecular biology and the Woodrow Wilson School of Public and International Affairs at Princeton University.

He has also helped with strategy development for global health agencies tackling bioterrorism and emerging diseases such as pandemic influenza and SARS.

Before joining Merck, Dr Mahmoud served as chair of the department of medicine and physician-in-chief at Case Western Reserve University School of Medicine and University Hospitals of Cleveland.

28th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics